Alternating Decitabine-Azacytidine Dosing to Bypass Drug Catabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical results with decitabine or 5-azacytidine for treating solid tumor malignancies, alone or in combination with immune checkpoint blockers, have not been as effective as predicted by pre-clinical data due to uneven tissue distribution and rapid catabolism by cytidine deaminase, leading to minimal molecular pharmacodynamic effects in lung cancer tissues.
Innovation Solution
Administering decitabine and 5-azacytidine alternately with a cytidine deaminase inhibitor, such as tetrahydrouridine, to bypass auto-dampening and exploit cross-priming, with specific timing between cycles to enhance DNMT1-depletion and immune recognition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If decitabine or 5-azacytidine is administered to treat solid tumor malignancies, then DNMT1 depletion and immune recognition are enhanced, but the drugs are rapidly catabolized by cytidine deaminase leading to minimal molecular pharmacodynamic effects in lung cancer tissues
Solution Approach 1:
Tetrahydrouridine (THU) is introduced as an intermediary substance that selectively inhibits cytidine deaminase in lung cancer tissues. This mediator blocks the catabolic pathway of decitabine and 5-azacytidine without affecting their therapeutic mechanism, thereby resolving the contradiction between drug efficacy and drug catabolism
Solution Approach 2:
The invention changes the kinetic parameters of drug metabolism by introducing THU, which alters the rate of cytidine deaminase activity. This parameter change extends the half-life of decitabine and 5-azacytidine in lung cancer tissues, allowing sufficient time for DNMT1 depletion and immune recognition effects to occur
2Reliability
If decitabine is administered continuously to maintain effective drug levels, then myelosuppression occurs at high concentrations, but alternate administration with 5-azacytidine can exploit cross-priming to enhance efficacy while reducing toxicity
Solution Approach 1:
The invention implements periodic administration of decitabine and 5-azacytidine in alternating cycles rather than continuous dosing. This periodic action allows lung cancer tissues to accumulate drug effects through cross-priming while preventing sustained high concentrations that cause myelosuppression, thereby resolving the contradiction between therapeutic efficacy and toxicity
Solution Approach 2:
The alternating administration schedule is designed to exploit cross-priming effects where the first drug prepares the cellular environment for enhanced response to the second drug. This preliminary action mechanism allows lower individual doses to achieve greater cumulative pharmacodynamic effects, reducing the need for high concentrations that cause myelosuppression
3Device complexity
If decitabine is administered alone or with immune checkpoint blockers, then treatment is simplified, but clinical results have not been as effective as predicted by pre-clinical data due to uneven tissue distribution and rapid catabolism
Solution Approach 1:
Tetrahydrouridine serves as a targeted intermediary that specifically protects decitabine and 5-azacytidine from catabolism in lung cancer tissues without requiring complex combination regimens. This single intermediary addition resolves the contradiction by enhancing drug stability and tissue distribution while maintaining treatment simplicity
Solution Approach 2:
The invention creates a composite therapeutic approach by combining decitabine or 5-azacytidine with tetrahydrouridine. This composite formulation addresses the limitations of individual drugs by integrating protective and therapeutic functions, thereby improving clinical efficacy without significantly increasing regimen complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach increases the efficacy of decitabine and 5-azacytidine by maintaining effective drug levels in lung cancer tissues, enhancing immune recognition and cytoreduction, and augmenting the effects of immune checkpoint inhibitors.
Implementation Method 1
combined with an inhibitor of the enzyme cytidine deaminase (e.g., tetrahydrouridine) that otherwise rapidly catabolizes decitabine and 5-azacytidine
Implementation Method 2
DNMT1-depletion by the pyrimidine nucleoside analogs decitabine or 5-azacytidine increased expression of MHC molecules and associated immune co-stimulatory molecules
Data Source
AI summary
Provided herein are compositions, systems, kits, and methods for treating a patient with cancer by alternate administration of decitabine and 5-azacytidine, or administration of decitabine two times per week on consecutive days, which is generally timed to bypass auto-dampening and exploit cross-priming. Such administration is combined with an inhibitor of the enzyme cytidine deaminase (e.g., tetrahydrouridine) that otherwise rapidly catabolizes decitabine and 5-azacytidine. In certain embodiments, the time between cycles of decitabine and 5-azacytidine administration is about three to four days or five to ten days.